...P.E. Sawchenko Single and dual immunohistochemical staining techniques were used to assay the effects of disruption of brain stem catecholaminergic inputs on corticotropin-releasing factor (CRF) and arginine vasopressin (AVP) immunoreactivity in parvocellular neurosecretory neurons...

...Markus V. Graf; Abba J. Kastin; David H. Coy; Alan J. Fischman It has been reported that delta-sleep-inducing peptide (DSIP) can affect several activities other than sleep, including reduction of stress. We studied the effects of this nonapeptide on corticotropin releasing factor (CRF)-stimulated...

...Miklos Palkovits; Michael J. Brownstein; Wylie Vale Insheep, 26 brain areas of 62 investigated contained corticotropin releasing factor (CRF)-like immunoreactivity in concentrations higher than 0.5 ng CRF/mg protein. Most of the CRF in the brain was in the hypothalamus. The highest level of CRF...

... corticotropin releasing factor (CRF), arginine vasopressin (AVP) and oxytocin (OXY); and to determine whether a central or peripheral locus is the primary site of action of the peptide. Injection of AII (1 and 5 μg, i.p.) in intact unanesthetized male rats, resulted in an increase in plasma ACTH and β-endorphin...

...R. Guillet; S.M. Michaelson Plasma ACTH concentrations were determined in neonatal rats 1, 7, 14, and 21 days old, subjected to treatment with either a median eminence extract with corticotropin releasing factor (CRF) activity or to ether exposure. ‘CRF’ injection elevated plasma ACTH levels on all...

...L.W. Swanson; P.E. Sawchenko; J. Rivier; W.W. Vale The distribution of corticotropin-releasing factor (CRF)-immunoreactive cells and fibers has been examined in the brains of normal adult rats, and in the brains of animals that had been pretreated with intraventricular injections of colchicine...